Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.

1st Department of Pathological Anatomy St Anne's University Hospital Pekarska 53 656 91 Brno Czech Republic

1st Orthopedic Department St Anne's University Hospital Brno Czech Republic

2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Clinic of Comprehensive Cancer Care of Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology Motol University Hospital Prague Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine and Faculty of Science Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Ann Surg. 1999 Jul;230(1):79-86 PubMed

Pediatr Hematol Oncol. 2012 Feb;29(1):1-11 PubMed

Acta Oncol. 2013 May;52(4):767-75 PubMed

Tumori. 2014 Jul-Aug;100(4):452-8 PubMed

Arch Surg. 2003 Mar;138(3):281-5 PubMed

Cancer Epidemiol. 2013 Feb;37(1):29-33 PubMed

Jpn J Clin Oncol. 2012 May;42(5):420-6 PubMed

J Clin Oncol. 2004 Jul 15;22(14):2873-6 PubMed

J Cancer Res Clin Oncol. 2007 Jan;133(1):1-11 PubMed

Eur J Cancer. 2002 Nov;38(17):2243-51 PubMed

J Clin Oncol. 1997 Jul;15(7):2611-21 PubMed

N Engl J Med. 2003 Feb 20;348(8):694-701 PubMed

J Clin Oncol. 2010 Jul 10;28(20):3284-91 PubMed

Ann Oncol. 2011 May;22(5):1221-7 PubMed

Onkologie. 2008 Dec;31(12):657-63 PubMed

J Pediatr Hematol Oncol. 2015 Jul;37(5):e278-84 PubMed

Sarcoma. 2013;2013:681425 PubMed

J Clin Oncol. 1998 Dec;16(12):3736-43 PubMed

J Clin Oncol. 2000 Sep;18(17):3108-14 PubMed

Cancer. 2010 Apr 15;116(8):1964-73 PubMed

Med Oncol. 2013 Mar;30(1):469 PubMed

Histopathology. 2014 Jan;64(1):134-50 PubMed

Jpn J Clin Oncol. 2004 Nov;34(11):667-72 PubMed

J Clin Oncol. 2006 Aug 20;24(24):3997-4002 PubMed

Cancer Epidemiol. 2015 Apr;39(2):189-95 PubMed

J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30 PubMed

Acta Oncol. 2000;39(1):111-6 PubMed

Cancer. 2010 Jul 1;116(13):3189-94 PubMed

J Clin Oncol. 2006 Jan 1;24(1):152-9 PubMed